Harvard Bioscience Financial Performance Overview
Harvard Bioscience, Inc. (NASDAQ: HBIO) recently shared its financial results for the fourth quarter and the full year. This release showcases the company’s performance amidst a myriad of market challenges.
Fourth Quarter Results Recap
Key Financial Highlights
For the fourth quarter of 2024, revenues reached approximately $24.6 million, down from $28.2 million in the same period last year. This decline indicates a cautious market response, particularly influenced by a reduction in purchasing from U.S. academic customers. In this quarter, the gross margin was noted at 57.1%, slightly lower than the previous year's figure of 58.0%. This difference can be attributed to lower absorption of fixed manufacturing costs and fluctuations in foreign exchange rates.
Profitability and Operational Metrics
Net income for the fourth quarter stood at $18 thousand, a significant recovery from the loss of $1.8 million reported a year earlier. Adjusted EBITDA for this quarter totaled $3 million, a drop from $3.6 million in the same period of 2023. Cash flow from operations was reported at $1.7 million, down from $4.3 million last year.
Annual Financial Performance
Annual Revenue Assessment
In the full year ending December 31, 2024, the total revenue decreased to $94.1 million from $112.3 million in 2023. This decline reflects ongoing challenging conditions faced by contract research organizations, distributors, and academic institutions due to budget cuts and transformations in spending patterns.
Full Year Margin and Profit Figures
The gross margin for 2024 was reported as 58.2% compared to 58.9% in the prior year. A net loss was highlighted at $12.4 million for the year, contrasting with a loss of $3.4 million the year before. This dip is largely attributed to lower revenues but was partially mitigated by reduced manufacturing and operational costs stemming from ongoing cost-saving measures.
Looking Ahead: Guidance for Q1 2025
Projected Revenue and Gross Margin
With uncertainties continuing in NIH funding and shifts in academic purchasing behaviors, Harvard Bioscience forecasts Q1 2025 revenues between $19 million and $21 million, alongside expected gross margin levels of 56% to 58%. Management remains committed to monitoring costs to enhance financial performance.
Engagement with Analysts and Investors
The company will conduct a conference call and a webcast to further discuss these results with analysts and investors, encouraging participation through prior registration for dial-in details.
About Harvard Bioscience
Harvard Bioscience is renowned for developing and manufacturing technologies crucial for life science applications, catering to academic institutions, government laboratories, and leading pharmaceutical firms. Its broad operational scope spans across multiple continents, enabling distribution worldwide.
Frequently Asked Questions
What were Harvard Bioscience's total revenues for 2024?
The total revenues for Harvard Bioscience in 2024 were $94.1 million.
How did the fourth quarter of 2024 compare to the previous year?
In the fourth quarter of 2024, revenues declined to $24.6 million from $28.2 million the previous year.
What was the adjusted EBITDA for the fourth quarter 2024?
The adjusted EBITDA for the fourth quarter of 2024 was $3.0 million.
What are the revenue forecasts for the first quarter of 2025?
Harvard Bioscience projects revenues of $19 million to $21 million for Q1 2025.
Who can potential investors contact for more information?
Potential investors can reach out to Jennifer Cote, the Chief Financial Officer, at (508) 893-3120 or via email at investors@harvardbioscience.com.
